论文部分内容阅读
目的:探讨紫杉醇联合地西他滨对晚期胃癌患者血清癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原72-4(CA72-4)水平的影响。方法:收集2013年10月-2015年1月于我院住院治疗的晚期胃癌患者122例,随机分为实验组和对照组。实验组患者给予紫杉醇和地西他滨化疗,对照组患者给予紫杉醇和安慰剂化疗。观察并比较两组患者治疗前后卡氏积分、血常规、血尿素氮、肌酐、转氨酶含量以及血清CA199、CEA及CA724水平的变化情况。结果:治疗后,两组患者的卡氏积分均较治疗前明显升高,血清CEA、CA19-9、CA72-4水平均较治疗前显著降低,且实验组的卡氏积分显著高于对照组,血清CEA、CA19-9、CA72-4水平明显低于对照组,差异均具有统计学意义(P<0.05)。治疗前后,两组患者的白细胞、血红蛋白及血小板水平比较均无统计学差异(P>0.05)。结论:紫杉醇联合地西他滨能有效降低晚期胃癌患者血清CEA、CA19-9、CA72-4水平,并提高患者的生存质量,且安全性较好。
Objective: To investigate the effect of paclitaxel and decitabine on serum CEA, CA19-9 and CA72-4 levels in patients with advanced gastric cancer. Methods: A total of 122 patients with advanced gastric cancer hospitalized in our hospital from October 2013 to January 2015 were randomly divided into experimental group and control group. Patients in the experimental group were treated with paclitaxel and decitabine, while patients in the control group were given paclitaxel and placebo. The changes of cardiogram, blood routine test, blood urea nitrogen, creatinine, transaminase, serum CA199, CEA and CA724 levels before and after treatment were observed and compared between the two groups. Results: After treatment, the Karnaugh’s score of both groups were significantly higher than before treatment, serum CEA, CA19-9, CA72-4 levels were significantly lower than before treatment, and the experimental group’s card score significantly higher than the control group , Serum CEA, CA19-9, CA72-4 levels were significantly lower than the control group, the difference was statistically significant (P <0.05). Before and after treatment, the two groups of patients with leukocyte, hemoglobin and platelet levels were no significant difference (P> 0.05). Conclusion: Paclitaxel combined with decitabine can effectively reduce the serum levels of CEA, CA19-9 and CA72-4 in patients with advanced gastric cancer, and improve the quality of life of patients with good safety.